Methods of producing high specific activity Sn-117m with commercial cyclotrons

  • Nigel R. Stevenson
  • George St. George
  • Jaime Simón
  • Suresh C. Srivastava
  • David W. Mueller
  • Gilbert R. Gonzales
  • Jason A. Rogers
  • R. Keith Frank
  • Ian M. Horn


Sn-117m is a theragnostic isotope of increasing interest. It has ideal imaging and therapeutic properties for many applications. Production of high specific activity Sn-117m can only be achieved with accelerators and the Sb(p,x) and Cd-116(α,3n) reactions provide the highest yields for this isotope. This paper describes the production and a new purification method for obtaining commercial quantities of Sn-117m via the Cd-116(α,3n) reaction. The purified Sn-117m has subsequently been chelated with an aminobenzyl derivative of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and then conjugated with annexin V-128 to produce an agent for the diagnosis and treatment of vulnerable plaque.


Sn-117m Theragnostic Accelerator produced isotope High specific activity 



The authors acknowledge the pioneering work of Dr. Claude Meares and his group at the University of California, Davis in forming [Sn-117m]-DOTA linked molecules. The authors would also like to thank the staff at the University of Washington MC50 Cyclotron for providing irradiation services in the production of Sn-117m. This work was supported in part by the US Department of Energy (Office of Science/NP Office of Nuclear Physics, Isotope Development and Production for Research and Applications) SBIR Program and the NNSA NA-24 GIPP Program, under Contract # DE-AC02-98CH10886 at Brookhaven National Laboratory. The work described here is the subject of US Patents 8,257,681, 8,283,167, 8,632,748, 8,097,064, 8,449,816, 8,705,681, 8,290,110, including continuations and international counterparts.


  1. 1.
    Krishnamurthy GT et al (1997) J Nucl Med 38:230–237Google Scholar
  2. 2.
    Bishayee A et al (2000) J Nucl Med 41:2043–2050Google Scholar
  3. 3.
    Swailem FM et al (1998) Nucl Med Biol 25:279–287CrossRefGoogle Scholar
  4. 4.
    Qaim SM, Dohler H (1984) Int J Appl Radiat Isot 35(7):645–650CrossRefGoogle Scholar
  5. 5.
    Fukushima S et al (1963) Bull Chem Soc Jpn 36(10):1225–1228CrossRefGoogle Scholar
  6. 6.
    Montgomery DM, Porile NT (1969) Nucl Phys A 130:65–76CrossRefGoogle Scholar
  7. 7.
    Adam Rebeles R et al (2008) Nucl Instrum Methods B266:4731–4737CrossRefGoogle Scholar
  8. 8.
    Maslov OD et al (2011) Appl Radiat Isot 69:965–968CrossRefGoogle Scholar
  9. 9.
    Ghosh K et al (2013) J Radioanal Nucl Chem 295:865–870CrossRefGoogle Scholar
  10. 10.
    Nortier M, Stevenson NR, Gelbart W (1995) Nucl Instrum Meth A355:236–241CrossRefGoogle Scholar
  11. 11.
    Dorman E, Emery R (2014) Isotope production and clinical research at the University of Washington clinical cyclotron, 8th international conference on isotopes, ChicagoGoogle Scholar
  12. 12.
    Srivastava SC (2012) Semin Nucl Med 42:151–163CrossRefGoogle Scholar
  13. 13.
    Srivastava SC (2006) In: Mazzi U (ed) Technetium, rhenium, and other metals in chemistry and nuclear medicine. SG Editorial, Padova, pp 553–568Google Scholar
  14. 14.
    Mausner LF, Mirzadeh S, Srivastava SC (1992) Appl Radiat Isot 43:1117–1122CrossRefGoogle Scholar
  15. 15.
    Srivastava SC et al (1998) Clin Cancer Res 4:61–68Google Scholar
  16. 16.
    Ermolaev SV et al (2009) J Radioanal Nucl Chem 280:319–324CrossRefGoogle Scholar
  17. 17.
    Mausner LF et al (1998) Appl Radiat Isot 49:285–294CrossRefGoogle Scholar
  18. 18.
    Stevenson NR, Horn IM (2012) US Patent 8,257,681Google Scholar
  19. 19.
    Simon J et al (2013) Sn-117m labeled annexin for vulnerable plaque, American Chemical Society Annual meeting, New Orleans, USAGoogle Scholar
  20. 20.
    Stevenson NR (2013) Production and applications of high specific activity Sn-117m labeled compounds, Radiometals 2013, Sonoma Valley, CA, USAGoogle Scholar
  21. 21.
    Simon J et al (2014) Preparation and evaluation of Sn-117m annexin for vulnerable plaque, proceedings 8th international conference on isotopes, Chicago, USAGoogle Scholar
  22. 22.
    Zheng M (2007) Synthesis and medical application of bifunctional metal chelates, Ph.D. Dissertation, UC Davis, USAGoogle Scholar
  23. 23.
    Stevenson NR et al (2013) Production and applications of very high specific activity Sn-117m, American Chemical Society Annual meeting, New Orleans, USAGoogle Scholar
  24. 24.
    Gonzales GR (2012) Tin-117m-DOTA-Annexin for imaging and treating vulnerable plaque, international conference on radiopharmaceutical therapy (ICRT/WARMTH), FinlandGoogle Scholar
  25. 25.
    Jaimovich R et al (2013) Sn117m-DOTA-annexin as a novel vulnerable plaque tracer: first time in humans trial, IAEA International Conference on Integrated Medical Imaging in cardiovascular disease, Vienna, AustriaGoogle Scholar
  26. 26.
    Srivastava SC, Narula J, Strauss HW, Gonzales G (2013) Simultaneous imaging and treatment of vulnerable plaques with tin-117m-DOTA-Annexin, WIPR 2013: latest progress in the field of radio immunotherapy, Nantes, FranceGoogle Scholar
  27. 27.
    Stevenson NR et al (2013) Manufacturing and integrated medical imaging of high specific activity [Sn-117m]-annexin in cardiovascular disease, IAEA International Conference on Integrated Medical imaging in cardiovascular disease, Vienna, AustriaGoogle Scholar
  28. 28.
    Strauss HW et al (2013) Targeting of vulnerable plaque using [tin-117m]-DOTA-annexin. Vancouver, CanadaGoogle Scholar
  29. 29.
    Srivastava SC et al (2013) Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque, Annual meeting of the society of nuclear medicine and molecular imaging, Vancouver, CanadaGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2015

Authors and Affiliations

  • Nigel R. Stevenson
    • 1
  • George St. George
    • 2
  • Jaime Simón
    • 2
  • Suresh C. Srivastava
    • 3
  • David W. Mueller
    • 1
  • Gilbert R. Gonzales
    • 1
  • Jason A. Rogers
    • 2
  • R. Keith Frank
    • 2
  • Ian M. Horn
    • 4
  1. 1.Clear Vascular, Inc.The WoodlandsUSA
  2. 2.IsoTherapeutics Group LLCAngletonUSA
  3. 3.Brookhaven National LaboratoryUptonUSA
  4. 4.US RadiopharmaceuticalsDentonUSA

Personalised recommendations